Modern perspectives on the treatment of non-alcoholic fatty liver disease with Metadoxine

Modern perspectives on the treatment of non-alcoholic fatty liver disease with Metadoxine

Authors

  • Rusudan Kvanchakhadze David Aghmashenebeli University Of Georgia
  • Nestan Bostoghanashvili The University of Georgia
  • Tamar Shervashidze David Aghmashenebeli University Of Georgia
  • Liana Jashi AVICENNA - Batumi Medical University

DOI:

https://doi.org/10.52340/spectri.2024.10.01.19

Keywords:

nonalcoholic fatty liver disease, hepatoprotective effect, metadoxine

Abstract

Non-alcoholic fatty liver disease is a dystrophic dysmetabolic disease of the liver, caused by excessive accumulation of lipids in hepatocytes, with subsequent liver dysfunction and possible cirrhosis. Treatment of this disease should be directed to the risk factors and causes of the development of the disease, as well as to prevent the progression of the pathological process in the liver. In this regard, one of the effective means is metadoxine, which has a pronounced hepatoprotective effect, due to its membrane-stabilizing effect and is based on the ability to restore saturated and unsaturated free fatty acids. The resistance of hepatocytes to lipid peroxidation increases, metadoxine prevents the accumulation of triglycerides in hepatocytes, which significantly slows down the formation of liver cirrhosis.

Downloads

Download data is not yet available.

Author Biographies

Rusudan Kvanchakhadze, David Aghmashenebeli University Of Georgia

Associate Professor

Nestan Bostoghanashvili, The University of Georgia

Associate Professor

Tamar Shervashidze, David Aghmashenebeli University Of Georgia

PhD student

Liana Jashi, AVICENNA - Batumi Medical University

Associate Professor

References

Jinghua D, Yu L, Dongdong L, Yuemin N. IDDF2019-ABS-0026 Metadoxine prevents diet-induced non-alcoholic steatohepatitis in mice.

Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatology Research. 2005 Oct 1;33(2):72-6.

Shenoy KT, Balakumaran LK, Mathew P, Prasad M, Prabhakar B, Sood A, Singh SP, Rao NP, Zargar SA, Bignamini AA. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Journal of clinical and experimental hepatology. 2014 Jun 1;4(2):94-100.

Paternostro R, Trauner M. Current treatment of non‐alcoholic fatty liver disease. Journal of internal medicine. 2022 Aug;292(2):190-204

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World journal of gastroenterology. 2018 Aug 14;24(30):3361.

Downloads

Published

2025-08-01

How to Cite

Kvanchakhadze, R., Bostoghanashvili, N., Shervashidze, T., & Jashi, L. (2025). Modern perspectives on the treatment of non-alcoholic fatty liver disease with Metadoxine. Scientific Journal „Spectri“, 10(2). https://doi.org/10.52340/spectri.2024.10.01.19

Issue

Section

Articles
Loading...